Search research articles
Contact Us
Filters
Showing results (1-10 of 104) with videos related to
Page
of 11
Sort By:
Biometrical Journal. Biometrische Zeitschrift
|
September 16, 2006
Confirmatory clinical trials with an adaptive design
Armin Koch
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|
May 3, 2011
[Benefits and harms - two sides of the same medal?]
Armin Koch
Contemporary Clinical Trials
|
April 20, 2005
How much do we have to pay for how many interim analyses?
Armin Koch
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
January 8, 2010
The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia
Maria Isaac, Armin Koch
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
March 10, 2017
[Ethical aspects of clinical trials in rare diseases]
Joerg Hasford, Armin Koch
Journal of Biopharmaceutical Statistics
|
June 23, 2004
Hypothesis testing in the "gold standard" design for proving the efficacy of an experimental treatment relative to placebo and a reference
Armin Koch, Joachim Röhmel
Pharmaceutical Statistics
|
March 23, 2019
Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and Parke
Robert Hemmings, Armin Koch
Journal of Biopharmaceutical Statistics
|
January 8, 2014
Reliably basing conclusions on subgroups of randomized clinical trials
Armin Koch, Theodor Framke
Biometrical Journal. Biometrische Zeitschrift
|
July 4, 2015
Does it help that efficacy has been proven once we start discussing (added) benefit?
Armin Koch, Yvonne Ziert
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
July 19, 2017
Erratum to: Ethical aspects of clinical trials in rare diseases
Joerg Hasford, Armin Koch
Page
of 11
Search research articles
Search
Showing results (1-10 of 104) with videos related to
Sort By:
Page
of 11
Biometrical Journal. Biometrische Zeitschrift
|
September 16, 2006
Confirmatory clinical trials with an adaptive design
Armin Koch
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|
May 3, 2011
[Benefits and harms - two sides of the same medal?]
Armin Koch
Contemporary Clinical Trials
|
April 20, 2005
How much do we have to pay for how many interim analyses?
Armin Koch
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
January 8, 2010
The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia
Maria Isaac, Armin Koch
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
March 10, 2017
[Ethical aspects of clinical trials in rare diseases]
Joerg Hasford, Armin Koch
Journal of Biopharmaceutical Statistics
|
June 23, 2004
Hypothesis testing in the "gold standard" design for proving the efficacy of an experimental treatment relative to placebo and a reference
Armin Koch, Joachim Röhmel
Pharmaceutical Statistics
|
March 23, 2019
Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and Parke
Robert Hemmings, Armin Koch
Journal of Biopharmaceutical Statistics
|
January 8, 2014
Reliably basing conclusions on subgroups of randomized clinical trials
Armin Koch, Theodor Framke
Biometrical Journal. Biometrische Zeitschrift
|
July 4, 2015
Does it help that efficacy has been proven once we start discussing (added) benefit?
Armin Koch, Yvonne Ziert
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
July 19, 2017
Erratum to: Ethical aspects of clinical trials in rare diseases
Joerg Hasford, Armin Koch
Page
of 11